may be presented to patients by programs using different birth prevalence curves is minimized. From a clinical standpoint, consistency in the ®rst and second trimester maternal-age speci®c risks quoted to patients by different counsellors is clearly preferable. Estimates for survival based on the f
UTERINE MALFORMATION: A CAUSE OF ELEVATED MATERNAL SERUM ALPHA-FETOPROTEIN CONCENTRATIONS
✍ Scribed by SEPPO HEINONEN; MARKKU RYYNÄNEN; PERTTI KIRKINEN; SEPPO SAARIKOSKI
- Publisher
- John Wiley and Sons
- Year
- 1996
- Tongue
- English
- Weight
- 403 KB
- Volume
- 16
- Category
- Article
- ISSN
- 0197-3851
No coin nor oath required. For personal study only.
✦ Synopsis
This study was undertaken to investigate the association between uterine anomalies and unexplained elevated maternal serum alpha-fetoprotein (MSAFP) concentrations during the early second trimester. The incidence of uterine anomalies was retrospectively evaluated among pregnant women showing elevated ( > 2 3 multiples of the median) mid-trimester maternal serum AFP ( N = 3 12) concentrations in otherwise normal singleton pregnancies and then compared with that amongst patients from the same clinic showing normal serum AFP results (N=28 410). Basic clinical data of the study group were also analysed. The rate of diagnosed developmental uterine malformations in patients showing elevated MSAFP levels was 1 in 31, whereas the rate in the control group was 1 in 710 (3.2 per cent vs. 0.14 per cent). The relative risk was 22.1 [95 per cent confidence interval (CI) 11.143.71. Amniotic fluid (AF) concentrations of AFP were normal in the study group. Our preliminary observations suggest that elevated MSAFP in the second trimester may in some cases be explained as being solely a result of uterine anomaly. The fetal to maternal transfer of AFP occurs by a transplacental, not a transamniotic, route, since AFAFP concentrations were normal. Consequently, obstetricians taking care of these patients should take this possibility into account.
📜 SIMILAR VOLUMES
Increased levels of second trimester maternal serum alpha-fetoprotein (MSAFP) have long been established as a marker for neural tube defects (NTDs). In addition, decreased levels of maternal estriol in the third trimester have been reported in pregnancies with anencephalic fetuses. The purpose of th
Primary alpha-fetoprotein secreting ovarian tumors have been detected in pregnancy by markedly elevated midtrimester MSAFP accompanied by sonographically visualized adnexal masses. We present a recurrent mixed germ cell tumor manifesting only as a moderately elevated MSAFP screen. A 23-year-old para
From Antenatal Diagnostic Center referrals over 22 months, consultations for early-onset fetal growth restriction versus skeletal dysplasia were retrospectively identified. Those with elevated maternal serum alpha-fetoprotein (MSAFP) levels are the focus of this report. All had an early ultrasound c
Progressively since 1982 and as part of a nationwide programme for the diagnosis and prevention of genetic diseases, maternal serum alpha-fetoprotein (MS-AFP) screening and ultrasound fetal monitoring has been implemented in all pregnant women in Cuba. In Havana City, 328 983 pregnant women underwen